Erudio Healtherudio.com
Drug
Obrixtamig trials: what clinicians said in public
An HCP commentary report on 1 clinical trial studying obrixtamig: DAREON-NEC-1. It covers what clinicians said in public about one trial, on podcasts, videos and posts, every statement linked to its source. Below them, 1 more trial with public commentary and no report yet.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| DAREON-NEC-1 NCT07544654 · Boehringer Ingelheim | first-line DLL3-positive advanced extrapulmonary neuroendocrine carcinomas | Phase 3 | 58 | 6 | Focused | Nov 15, 2026 | Preview |
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| NCT05879978 NCT05879978 · Boehringer Ingelheim FocusedView → | DLL3-positive small cell lung cancer and neuroendocrine neoplasms | Phase 1 | Focused | View | |||